Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management
暂无分享,去创建一个
P. Fenici | J. Spaak | N. Kanumilli | D. Cherney | J. Vora | K. Khunti | Mikhail N. Kosiborod | C. S. Lam | Michael Bachmann
[1] S. Bungău. Cardio-Renal Metabolic Syndrome: Interdisciplinary Diagnostic Methods , 2023, Diagnostics.
[2] Eric L. Johnson,et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. , 2022, Diabetes care.
[3] K. Khunti,et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2022, Kidney international.
[4] Connie M. Rhee,et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.
[5] Deepak L. Bhatt,et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association , 2022, Circulation.
[6] E. Lerma,et al. Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities , 2021, Cardiorenal Medicine.
[7] N. Sattar,et al. Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention? , 2021, Circulation.
[8] K. Khunti,et al. Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study , 2021, Diabetic medicine : a journal of the British Diabetic Association.
[9] J. McEvoy,et al. Aspirin in the Modern Era of Cardiovascular Disease Prevention , 2021, Methodist DeBakey cardiovascular journal.
[10] I. V. Van Gelder,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.
[11] Neha J. Pagidipati,et al. A comprehensive cardiovascular-renal-metabolic risk reduction approach to patients with Type 2 Diabetes Mellitus. , 2021, The American journal of medicine.
[12] Chiadi E. Ndumele,et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.
[13] L. Tokgözoğlu,et al. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. , 2021, Anatolian journal of cardiology.
[14] J. McMurray,et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. , 2021, The lancet. Diabetes & endocrinology.
[15] Sathish Kumar Jayapal,et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.
[16] F. Giorgino,et al. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk , 2020, Cardiovascular Diabetology.
[17] M. Vaduganathan,et al. Cardio-Renal-Metabolic Care Models , 2020, Circulation. Cardiovascular quality and outcomes.
[18] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[19] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.
[20] K. Khunti,et al. Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. , 2020, Primary care diabetes.
[21] Ilia G. Halatchev,et al. A patient-centred, comprehensive model for the care for heart failure: the 360° heart failure centre , 2020, Open Heart.
[22] Pamela Mazzocato,et al. Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden , 2020, BMJ Open.
[23] J. O’Keefe,et al. Abstract 369: Secondary Risk Reduction in Patients With Type 2 Diabetes and Cardiovascular Disease: Experience From a Cardiometabolic Center of Excellence , 2020, Circulation: Cardiovascular Quality and Outcomes.
[24] M. Vaduganathan,et al. Training the Next Generation of Cardiometabolic Specialists. , 2020, Journal of the American College of Cardiology.
[25] Sanjiv J. Shah,et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity , 2020, European journal of heart failure.
[26] M. Evans,et al. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials , 2019, Diabetes Therapy.
[27] D. Wheeler,et al. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus , 2019, American Journal of Nephrology.
[28] Pamela Mazzocato,et al. Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic , 2019, Journal of multidisciplinary healthcare.
[29] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[30] Deepak L. Bhatt,et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.
[31] C. Lavie,et al. Obesity paradox in cardiovascular disease: where do we stand? , 2019, Vascular health and risk management.
[32] C. Ronco,et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. , 2019, Circulation.
[33] P. McFarlane,et al. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes , 2019, Current medical research and opinion.
[34] J. Spaak,et al. Health care professionals’ experiences and enactment of person-centered care at a multidisciplinary outpatient specialty clinic , 2019, Journal of multidisciplinary healthcare.
[35] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[36] A. Roddick,et al. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.
[37] P. Schauer,et al. Bariatric Surgery Decreases Mortality of Congestive Heart Failure: A Nationwide Study , 2018, Surgery for Obesity and Related Diseases.
[38] C. Ronco,et al. Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data , 2018, Cardiorenal Medicine.
[39] Björn Eliasson,et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.
[40] Jackson T. Wright,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.
[41] Sanjiv J. Shah,et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. , 2018, JACC. Heart failure.
[42] S. Arnold,et al. Burden of cardio‐renal‐metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry , 2018, Diabetes, obesity & metabolism.
[43] T. Einarson,et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.
[44] K. Khunti,et al. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? , 2018, Diabetes, obesity & metabolism.
[45] J. Shaw,et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. , 2018, Journal of the American College of Cardiology.
[46] P. Damman,et al. Optimal duration of dual antiplatelet therapy for coronary artery disease , 2018, Netherlands Heart Journal.
[47] E. Bonora,et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.
[48] B. Zinman,et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial , 2018, European heart journal.
[49] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[50] A. Khorana,et al. Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time , 2017, Clinical colorectal cancer.
[51] J. Metsemakers,et al. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands , 2017, The European journal of general practice.
[52] E. Han,et al. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases , 2017, Diabetes & metabolism journal.
[53] Neha J. Pagidipati,et al. Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[54] E. Loza,et al. Experience and satisfaction with a multidisciplinary care unit for patients with psoriasis an psoriatic arthritis. , 2017, Reumatologia clinica.
[55] I. D. de Boer,et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.
[56] M. Farkouh,et al. Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus , 2017, Cardiovascular Drugs and Therapy.
[57] C. Byrne,et al. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease , 2017, Nature Reviews Nephrology.
[58] Massimo F. Piepoli,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2017, International Journal of Behavioral Medicine.
[59] J. Spaak,et al. Novel Combined Management Approaches to Patients with Diabetes, Chronic Kidney Disease and Cardiovascular Disease , 2017, The journal of the Royal College of Physicians of Edinburgh.
[60] R. Rivera,et al. Multidisciplinary Care Models for Patients With Psoriatic Arthritis. , 2017, Reumatologia clinica.
[61] K. Khunti,et al. Aspirin for primary prevention of cardiovascular and all‐cause mortality events in diabetes: updated meta‐analysis of randomized controlled trials , 2017, Diabetic medicine : a journal of the British Diabetic Association.
[62] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[63] D. Atar,et al. Neurohormonal Blockade in Heart Failure. , 2016, Cardiac failure review.
[64] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[65] J. Radhakrishnan,et al. Cardio-renal syndrome , 2016, F1000Research.
[66] O. Pedersen,et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.
[67] Deepak L. Bhatt,et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.
[68] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[69] P. Grant,et al. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic , 2016, Herz.
[70] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[71] Merlin C. Thomas,et al. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease , 2016, Nature Reviews Nephrology.
[72] S. Friedman,et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.
[73] K. Rahimi,et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.
[74] Spiros Denaxas,et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.
[75] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[76] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[77] Shih-Jen Hwang,et al. Mid-adulthood risk factor profiles for CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[78] Jennette P. Moreno,et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.
[79] H. Keen,et al. The concomitants of raised blood sugar: studies in newly-detected hyperglycaemics: II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. , 2014, International journal of epidemiology.
[80] F. Mallamaci,et al. Obesity and CKD progression: hard facts on fat CKD patients. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[81] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[82] N. Sattar,et al. Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.
[83] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[84] O. Djurdjev,et al. Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[85] O. Djurdjev,et al. The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease , 2012, Pediatric Nephrology.
[86] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[87] R. Bergenstal,et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2012, Diabetologia.
[88] L. Ruilope,et al. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension , 2012, Journal of hypertension.
[89] Josef Coresh,et al. Chronic kidney disease , 2012, The Lancet.
[90] Patrick J Heagerty,et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.
[91] T. Wadden,et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.
[92] B. Massie,et al. Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2011, Circulation. Heart failure.
[93] Amitabh Srivastava,et al. Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma. , 2010, Journal of oncology practice.
[94] R. Cottrell,et al. A review and meta-analysis of the effect of weight loss on all-cause mortality risk , 2009, Nutrition Research Reviews.
[95] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[96] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[97] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[98] R. Bilous,et al. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[99] G. Fonarow,et al. Body mass index and mortality in heart failure: a meta-analysis. , 2008, American heart journal.
[100] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[101] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.
[102] H. Parving,et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. , 2006, Kidney international.
[103] Rury R Holman,et al. Risk Factors for Renal Dysfunction in Type 2 Diabetes , 2006, Diabetes.
[104] Carlos Iribarren,et al. Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.
[105] A. Levin,et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. , 2005, Journal of the American Society of Nephrology : JASN.
[106] R. Collins,et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.
[107] Florian Kronenberg,et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.
[108] M. Mauer,et al. Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.
[109] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[110] Samy I McFarlane,et al. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management , 2004, Current hypertension reports.
[111] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[112] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[113] R. Peto,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[114] W. Rand,et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.
[115] J. Coresh,et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.
[116] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[117] S. Bianchi,et al. Hyperinsulinemia, circadian variation of blood pressure and end-organ damage in hypertension. , 1997, Journal of nephrology.
[118] M. Inaba,et al. Insulin resistance in non-obese, non-insulin-dependent diabetic patients with diabetic nephropathy. , 1997, Metabolism: clinical and experimental.
[119] J. Singer,et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[120] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[121] K. McPherson,et al. Secondary prevention of vascular disease by prolonged antiplatelet treatment , 1988, British medical journal.
[122] R. DeFronzo,et al. Insulin resistance in uremia. , 1981, The Journal of clinical investigation.
[123] J. Goodall,et al. Treatment of hypertension. , 1960, The Central African journal of medicine.
[124] Daxin Wang,et al. Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks". , 2019, Circulation.
[125] Diabetes Federation. IDF Diabetes Atlas 9th Edition , 2019 .
[126] Diane M. Miller,et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.
[127] K. Koh. “ Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs : The CVD-REAL Study ( Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors ) , 2018 .
[128] H. Parving,et al. Microalbuminuria: a parameter that has changed diabetes care. , 2015, Diabetes research and clinical practice.
[129] A. Aplogan,et al. From the Centers for Disease Control and Prevention , 2015 .
[130] R. Gansevoort,et al. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[131] S. Schinner. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[132] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.
[133] C. Ballantyne. Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) , 2003 .